[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-insufficiency":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,63,80,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100635424","clinical-study-on-the-preservation-of-ovarian-function-in-patients-with-aplastic-anemia-following-allogeneic-hematopoietic-stem-cell-transplantation-using-goserelin-100635424",false,"NCT07552506","Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin","Inclusion Criteria:\n\n(1) Patients clinically diagnosed with SAA and scheduled for allogeneic haematopoietic stem cell transplantation (allo-HSCT); (2) Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; (3) Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating comprehension and willingness to comply with all study procedures and requirements; (4) Patients with an estimated survival period exceeding one year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n(1) Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; (2) Patients with a history of allergy to goserelin or related medications; (3) Patients who have previously undergone menopause due to physiological or pathological factors; (4) Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; (5) Patients currently participating in other clinical studies that may influence menstrual recovery; (6) Patients who refuse to participate in this clinical study.","FEMALE","14 Years","50 Years",{"count":19,"type":20},132,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a prospective, randomized, controlled, multicenter clinical trial. It plans to enroll 132 female SAA patients aged 14-50 years from multiple medical centers nationwide who are scheduled to undergo allo-HSCT. Patients will be divided into two groups based on whether they receive busulfan conditioning: the busulfan-conditioned group (Bu group) and the non-busulfan-conditioned group (non-Bu group). Within each group, patients will be randomly assigned 1:1 to either the experimental group (Goserelin prophylaxis group) or the control group using a random number table. The experimental group will receive a single 3.6 mg subcutaneous injection of Goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group will not receive Goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplant (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Additional reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil\u002Fplatelet engraftment; incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; transplant-related mortality; and adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in preserving ovarian function following allo-HSCT.",[26,27,28],"Aplastic Anaemia (AA)","Allogeneic Haematopoietic Stem Cell Transplantation","Ovarian Insufficiency",[30,31,32],"Aplastic anaemia","Allogeneic haematopoietic stem cell transplantation","Ovarian insufficiency","NOT_YET_RECRUITING","2026-04-20",{"date":36,"type":37},"2026-04-27","ACTUAL",{"date":39,"type":20},"2026-05-01",{"date":41,"type":20},"2027-10-01",{"name":43,"class":44},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":61,"leadSponsor":62,"locationsCount":5},"100635422","clinical-study-on-the-preservation-of-ovarian-function-following-hematopoietic-stem-cell-transplantation-in-patients-with-malignant-hematologic-diseases-using-goserelin-100635422","NCT07552480","Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin","Inclusion Criteria:\n\n1\\. Patients with malignant hematologic disorders scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating ability to understand and comply with all study procedures and requirements; 4. Expected survival exceeding 1 year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n1\\. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may affect study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or other related medications; 3. Patients who have already undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may affect menstrual recovery; 6. Patients who refuse to participate in this clinical study.",{"count":52,"type":20},64,[23],"This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female patients with malignant hematologic diseases aged 14-50 years who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The non-MAC group refers to a primary conditioning regimen where the main conditioning agents-busulfan (Bu) ≤ 6.4 mg\u002Fkg, melphalan (Mel) ≤ 140 mg\u002Fm², and thiotepa ≤ 10 mg\u002Fkg-are combined. Patients receiving this primary chemotherapy regimen will be assigned to the MAC group. Within each group (MAC or non-MAC), patients were randomly assigned 1:1 to either the experimental group (goserelin prophylaxis) or the control group using a random number table. The experimental group received a single 3.6 mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation. Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; other reproductive indicators: ovarian volume, endometrial thickness; Neutrophil\u002Fplatelet engraftment time; Complications: incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; Disease recurrence rate; Transplant-related mortality; Adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in improving ovarian function following hematopoietic stem cell transplantation in patients with malignant hematologic diseases.",[27,56,28],"Malignant Hematologic Disease",[58,31,32],"Malignant Hematologic Diseases",{"date":36,"type":37},{"date":39,"type":20},{"date":41,"type":20},{"name":43,"class":44},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":79,"locationsCount":5},"100635423","clinical-study-on-the-preservation-of-ovarian-function-following-autologous-hematopoietic-stem-cell-transplantation-using-goserelin-100635423","NCT07552493","Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin","Inclusion Criteria:\n\n1\\. Haematological patients scheduled for autologous haematopoietic stem cell transplantation; 2. Female patients aged 14 to 50 years with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives must voluntarily participate and sign an informed consent form, demonstrating comprehension and willingness to comply with all study procedures and requirements; 4. Estimated survival exceeding one year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n1\\. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or related medications; 3. Patients who have previously undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may influence menstrual recovery; 6. Patients who refuse to participate in this clinical study.",{"count":52,"type":20},[23],"This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female hematologic patients aged 14 to 50 years scheduled for autologous hematopoietic stem cell transplantation (auto-HSCT). Participants will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The conditioning regimen for autologous hematopoietic stem cell transplantation primarily employs melphalan. A melphalan dose \\>140 mg\u002Fm² constitutes myeloablative conditioning (MAC), while a dose ≤140 mg\u002Fm² is classified as non-myeloablative conditioning. Within each group, patients were randomly assigned 1:1 to the experimental group (goserelin prophylaxis) or control group using a random number table. The experimental group received a single 3.6mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Other reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil\u002Fplatelet engraftment; disease recurrence rate; transplant-related mortality; and adverse event (AE) incidence. This study aims to evaluate the efficacy of goserelin in improving ovarian function following autologous hematopoietic stem cell transplantation in hematologic malignancy patients.",[28,73],"Autologous Hematopoietic Stem Cell Transplantation",[75,32],"Autologous haematopoietic stem cell transplantation",{"date":36,"type":37},{"date":39,"type":20},{"date":41,"type":20},{"name":43,"class":44},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":15,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":100,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100567808","ovarian-tissue-allo-transplantation-100567808","NCT06673004","Ovarian Tissue Allo-transplantation","Ovarian Tissue Allo-Transplantation in the Setting of Primary Ovarian Insufficiency Between Non-Genetically Identical Siblings With Use of Immunosuppression","Inclusion Criteria (Donor):\n\n* Must meet criteria for ovarian sufficiency: Menstruating; Premenopausal serum hormone (FSH, LH, estradiol, AMH) levels\n* Must be between the ages of 21-35 years old.\n* Must be genetic sister to recipient participant, which will be assessed by patient report.\n* Must have history of at least one healthy live birth.\n* Must have more than one ovary (i.e. must have both the left and right ovary).\n* Must be willing to undergo a donor transplant evaluation including serologies and nucleic acid testing (NAT, which is essentially rapid PCR) for infectious conditions.\n* Must have normal female karyotype (46,XX).\n* Must have negative testing for HIV type 1 and 2, Hepatitis B, Hepatitis C, syphilis, West Nile Virus, gonorrhea and chlamydia.\n* Must be willing to undergo general anesthesia, minimally invasive gynecologic surgery, and loss of unilateral ovary.\n* If patient is a smoker, 3 months cessation is required prior to enrollment and must pass a nicotine test.\n* Must be willing and able to sign informed consent and follow all outlined procedures and recommendations in the protocol.\n* Donors (with their marital partners, when applicable) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.\n\nInclusion Criteria (Recipient):\n\n* Must meet criteria for primary ovarian insufficiency: Amenorrheic x12 months; Serum hormone (FSH, LH, estradiol, AMH) levels consistent with menopause\n* Must be between the ages of 21-40 years old.\n* Must be in a committed relationship with a male partner.\n* Must be willing to attempt natural conception within 4 months following transplant.\n* Must be willing to undergo a pre-transplant evaluation.\n* Must be willing to undergo Maternal Fetal Medicine consultation and evaluation for safety of pregnancy, particularly patients at risk of complications in pregnancy (e.g. Turner syndrome patients).\n* Must be willing to undergo general anesthesia, minimally invasive gynecologic surgery, pregnancy with potential high risk complications, and surgery to remove the graft\n* Must be willing and able to receive potent immunosuppressive medications and must be able to follow standard infection prophylaxis protocols\n* Must have been offered and declined donor oocyte IVF as a first line treatment option\n* Must be willing to receive standard vaccinations such as influenza, Hepatitis B. If age and circumstances indicate, be willing to receive vaccines against pneumococcus, HPV and Hepatitis A.\n* If patient is a smoker, 3 months cessation is required prior to enrollment and must pass a nicotine test.\n* Must be willing and able to sign informed consent and follow all outlined procedures and recommendations in the protocol, including assent for monitoring neonatal outcomes for the first year after birth.\n* Intended parents (meaning, the recipient and partner) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.\n\nInclusion Criteria (Recipient Male Partner)\n\n* Must be age 18 years or older (and a combined age not greater than 110 years).\n* Must have a normal semen analysis.\n* Must be willing and able to sign informed consent.\n* Intended parents (meaning, the recipient and partner) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.\n\nExclusion Criteria (Donor) (to be verified by history and review of the medical chart by the study team)\n\n* History of hypertension, diabetes, or significant heart, liver, kidney or central nervous system disease.\n* Any medical diagnosis placing the subject at high risk of surgical complications based on the team's review of medical history.\n* Current smoker (smoking cessation must have occurred 3 months prior to enrollment).\n* History of prior malignancy except for cervical cancer in stage 1a or 1b after 3 years.\n* History of human immunodeficiency virus (HIV), mycobacteria, hepatitis C.\n* Hepatitis B infection (Hepatitis B risk is for those with HepB surface antigen and\u002For HBV DNA positive. Those that are HepB core antibody true-positive are at minimal risk of reactivation. Those with vaccine-induced HepB surface antibody are not at risk).\n* Presence of active documented systemic infection or recent systemic infection within the past three months: Positive for syphilis (T. pallidum), chlamydia (C. trachomatis) or gonorrhea (N. gonorrhea).\n* BMI greater than 35 kg\u002Fm2\n\nExclusion Criteria (Recipient)\n\n* History of hypertension, diabetes, or significant heart, liver, kidney or central nervous system disease. Serum creatinine level \\>1.0 mg\u002FdL.\n* Any medical diagnosis placing the subject at high risk of surgical complications based on the team's review of medical history.\n* Current smoker (smoking cessation must have occurred 3 months prior to enrollment).\n* Active HPV infection.\n* History of prior malignancy except for cervical cancer in stage 1a or 1b after 3 years.\n* History of human immunodeficiency virus (HIV), mycobacteria, hepatitis C.\n* Hepatitis B infection (Hepatitis B risk is for those with HepB surface antigen and\u002For HBV DNA positive. Those that are HepB core antibody true-positive are at minimal risk of reactivation. Those with vaccine-induced HepB surface antibody are not at risk).\n* Presence of active documented systemic infection or recent systemic infection within the past three months.\n* Significant mental illness or substance abuse.\n* BMI greater than 30 kg\u002Fm2\n* Prior organ transplant with rejection, infection, or graft thrombosis.\n\nExclusion Criteria (Recipient Male Partner )\n\n* Inability to complete regular intercourse.\n* History of incarceration.\n* Significant mental illness or substance abuse.",true,"21 Years","40 Years",{"count":91,"type":20},10,[23],"Premature ovarian failure, also known as primary ovarian insufficiency (POI), or premature menopause, affects 1-2% of women under 40. The diagnosis is typically made based on high levels of follicle stimulating hormone (FSH) and absent or irregular menstrual periods. It leads to infertility and menopause-like effects (hot flashes and thin bones) due to low estrogen levels. POI can result from various factors such as genetic conditions, autoimmune diseases, or previous medical treatments like chemotherapy.\n\nTreatment of POI usually involves hormone replacement therapy and, if pregnancy is desired, assisted reproductive technologies such as in vitro fertilization (IVF) using an egg donor. However, IVF may not be an option for everyone due to personal, religious, ethical or financial reasons. Recent advances in medicine have identified ovarian tissue transplantation (OTT) as a potential solution. OTT involves transplanting either fresh or frozen ovarian tissue into the pelvic area, where it can begin functioning again. Studies in animals and humans have shown success in restoring hormonal function and even achieving pregnancies in some cases. Initial human trials of ovarian tissue transplants from another individual began with identical twins and have since expanded to include non-identical siblings with compatible tissue matches using immunosuppression. Success rates of OTT have been promising, with multiple live births reported between identical twins. Long-term studies indicate that transplanted tissue can remain functional for up to eight years. Ovarian tissue transplantation offers a promising avenue for women with POI to help restore fertility and hormonal function. Continued research and refinement of tissue techniques are essential to improve outcomes and expand access to this innovative treatment option.\n\nThis study will enroll 10 participants who will undergo ovarian tissue transplantation donated by a non-identical sister using an immunosuppression protocol at University Hospitals.",[95,28,96,97,98,99],"Ovarian Failure","Menopause Ovarian Failure","Menopause, Premature","Infertility, Female","Endocrine Female Infertility",[101,102,103,104,105,106],"Primary ovarian insufficiency","Ovarian tissue transplantation","Immunosuppression","Premature menopause","Ovarian failure","Ovary transplant","2026-03-05",{"date":109,"type":37},"2026-03-09",{"date":39,"type":20},{"date":112,"type":20},"2030-05-30",{"name":114,"class":44},"Rebecca Flyckt",1,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":87,"sex":15,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":115},"100453223","phase-2-autologous-platelet-rich-plasma-intraovarian-infusion-for-poor-responders-100453223","NCT05181748","Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders","Investigating the Efficiency of Autologous Platelet Rich Plasma Intraovarian Infusion on Improving Ovarian Functionality in Poor Ovarian Response Patients","PRPPOR","Inclusion Criteria:\n\nPoor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the following):\n\n1. Age ≥ 40 years\n2. AMH \\\u003C 1.1 ng\u002Fml OR AFC \\\u003C 7\n3. ≤ 3 oocytes with a conventional stimulation protocol\n\n   * Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement and acupuncture, for at least three months prior to recruitment.\n   * Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* Cycle irregularities\n* Amenorrhea\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of cancer in reproductive system\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for Preimplantation Genetic Testing (PGT) -Ovarian inaccessibility -Endocrinological disorders (Hypothalamus-\n* Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders","35 Years","47 Years",{"count":127,"type":20},100,[129,130],"PHASE2","PHASE3","Autologous platelet rich plasma (PRP) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (ICSI) treatment.",[133,98,28,95,134,135],"Poor Response to Ovulation Induction","Reproductive Sterility","Ovary; Anomaly",[137,138,139,140,141],"Autologous platelet rich plasma intraovarian infusion","Assisted reproduction","PRP","In vitro fertilization","Ovarian functionality improvement","RECRUITING","2024-12-20",{"date":145,"type":37},"2024-12-27",{"date":147,"type":37},"2019-01-23",{"date":149,"type":20},"2026-01-31",{"name":151,"class":44},"Genesis Athens Clinic"]